Saturday, 22 June 2024

Australia's most trusted
source of pharma news

Saturday, 22 June 2024
Listen to this story 

Court told to prevent 'mischief'

Posted 7 June 2024 AM

Pfizer has accused Samsung Bioepis of fishing for reasons to invalidate a patent in its legal stoush against the top-earning biosimilar in Australia.

Samsung Bioepis launched its Enbrel biosimilar, Brenzys, in Australia in 2017, and in the financial year ending June 2023 it was the highest earning biosimilar brand listed on the PBS. Enbrel and Brenzys earned a combined $101.2 million for the financial year 2023, with the biosimilar Brenzys earning $41.8 million of that.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (29)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (7)

Other (20)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.